ACTC - Advanced Cell Technology

[seagull339]

Advanced Cell Technology Announces Executive Promotions
Friday November 2, 9:00 am ET

LOS ANGELES--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB: ACTC) announced today that it has appointed Jonathan H. Dinsmore, Ph.D. to the position of Senior Vice President - Regulatory and Clinical and Ivan Wolkind to the position of Senior Vice President – Finance, Administration & Chief Accounting Officer. Dr. Dinsmore was previously the company’s Vice President and General Manager, while Mr. Wolkind was previously Vice President of Finance and Chief Accounting Officer.

“I am pleased to recognize the contributions of Jonathan and Ivan with expanded roles and responsibilities,” said William M. Caldwell, IV, its Chairman and Chief Executive Officer. “Today, Advanced Cell Technology has positioned itself to become a leading participant in the field of regenerative medicine, helped by the contributions of these talented executives.”

Dr. Jonathan H. Dinsmore was formerly responsible for all aspects of Mytogen’s cell production operations, basic science program, and research and development efforts. He was also actively engaged in evaluating partnership opportunities and complimentary technologies. Prior to his position with Advanced Cell Technology and Mytogen, he directed both clinical and preclinical research programs at Diacrin and GenVec. Dr. Dinsmore has research and clinical experience in the development of therapeutic products to treat Parkinson’s disease, Huntington’s disease, epilepsy, stroke, spinal cord injury, chronic intractable pain, liver disease, and cardiovascular disease. Dr. Dinsmore received a B.S. in Biology from Boston College followed by a Ph.D. in Biology from Dartmouth College. Dr. Dinsmore was a Post-doctoral fellow at MIT from 1989 to 1992. His extensive accomplishments include numerous awarded and pending patents as well as diverse published studies on myoblast transplantation technology.

Mr. Wolkind joined the company in May 2005. Prior to joining Advanced Cell, he served as the Executive Vice President of Finance and Chief Financial Officer for Eyematic, a technology company providing software solutions for delivering animated content to cell phones. Between 1999 and July 2001, Mr. Wolkind was the Chief Financial Officer for eLease, a company providing software solutions and back end automation for the capital equipment leasing market. Prior to his appointment at eLease, Mr. Wolkind served as the Vice President of Finance for Ventro Corporation, where he was instrumental in the raising of capital in the company’s initial public offering and subsequent debt offerings. Before his tenure at Ventro Corporation, Mr. Wolkind served as the Vice President of Finance at Onsale, Inc., a publicly traded Internet auction company. Prior to joining Onsale, he held key finance positions at two other companies after leaving KPMG, where he had worked in the financial services and banking audit group. Mr. Wolkind qualified as a Chartered Accountant in the United Kingdom.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts

Related News Stories
· Advanced Cell Technology to Present at The Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th - Business Wire (Thu Nov 1)
· ADVANCED CELL TECHNOLOGY, INC. Files SEC form 8-K, Change in Directors or Principal Officers - EDGAR Online (Thu Nov 1)
· Advanced Cell Technology's Chief Scientific Officer Delivers Keynote Address at Leading International Stem Cell Conference - Business Wire (Wed Oct 31)

ACTC $ 0.29
Advanced Cell Technology Inc. 0.00
Shares Short 1,032,200
Days to Cover (Short Ratio) 1.9
Short % of Float 1.91 %
Shares Short - Prior
Short % Increase / Decrease %
Squeeze RankingTM -2
% from 52-Wk HIGH ( 1.19 ) -310.34 %
% from 52-Wk LOW ( 0.26 ) 10.34 %
% from 200-Day MA ( 0.56 ) -93.10 %
% from 50-Day MA ( 0.47 ) -62.07 %
Price % Change (52-Wk) -61.30 %
Trading Volume - Today 356,851
Trading Volume - Average 549,700
Trading Volume Vs. Avg. 64.92 %
Total Shares - Float 54,000,000
Total Shares - Outstanding 62,621,037
% Held by Insiders 17.77 %
% Held by Institutions 0.40 %
Market Cap 18,160,101

........................

Been watching this and wonder what others might think?

[seagull339]

I'm in at .30 to see if it can break out of resistance at .31 Volume is building a bit early in day. Watching to see if it can break .32 on volume over 500K. Hasn't broken .32 since late August.

Needs to close above the 50ma at .30 for me to stay in.

[Titan]

Last time we played this, we played it from .32 to .37 and got out before it came crashing back down.

Unfortunately, todays news sure didn't seem to help it much and the charts tend to indicate its going to drop a bit lower.

We're going to wait for the RSI to get closer to, or below 25 and then start watching it on L2, looking for signs of the turn.

Hope I'm wrong and it turns around tomorrow and heads higher for you!!!

Good Luck!!!

[seagull339]

Originally Posted by Titan

Last time we played this, we played it from .32 to .37 and got out before it came crashing back down.

Unfortunately, todays news sure didn't seem to help it much and the charts tend to indicate its going to drop a bit lower.

We're going to wait for the RSI to get closer to, or below 25 and then start watching it on L2, looking for signs of the turn.

Hope I'm wrong and it turns around tomorrow and heads higher for you!!!

Good Luck!!!

Thanks for your input. I got out with a small loss. One of my latest trading plan rules is if it doesn't perform in the right direction within 45-90 minutes after entry even though it may not have hit my sell stop. Get out! Even get out within the first 30 minutes if I don't like the volume or whatever else doesn't feel right.

I don't know how to watch L2 for a turn. RSI I understand. Maybe you can post a heads up if you think it is turning. I'll keep watching.

I knew this was a low possibilities trade until they have some breakthough but I need the experience anyway.

[mike_d]

look at the chart on this one everyone, im not in... no cash flow riht now.

[bodeen]

If they would ever approve the use of stemcells this would probably be a money making stock.

[mike_d]

Originally Posted by mike_d

look at the chart on this one everyone, im not in... no cash flow riht now.

up nearly 70% today, wish i would ahve got a position.

[bodeen]

Does anyone think that ACTC will be a double digit stock someday like 50.00 pps?

[BullishBear]

Originally Posted by bodeen

Does anyone think that ACTC will be a double digit stock someday like 50.00 pps?

could be. i have some concern of their fianances. it seems like the pps dropped 50% overnight last year due to some requirment they had, dilution of some sort. and it depends on who takes the white house. even though they are generating these form other stem cells, ignorant people will see no difference. stem cell bad. ya know? and i thoguht they published these same findings last year sometime, because some scientists called them liars.

[greencat]

Possible bounce play. I will not play it. But for the bottom bounce players it may be of interest..